ALK and non-small cell lung carcinoma: Likewise, these data highlight the benefit of alectinib in the first-line setting for ALK-positive NSCLC as reflected in the National Comprehensive Cancer Network (NCCN) guidelines, the European Society for Medical Oncology (ESMO) guidelines, and the Italian Association of Medical Oncology (AIOM) guidelines, which recognize alectinib as a better first-line treatment option than crizotinib [29,30,31].